FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax's partners, all reformulated to target the XFG variant, giving clinicians several options ahead of the fall respiratory virus season.
|Articles|September 23, 2020
Promising News with Regards to COVID-19 Mothers and Newborns
Author(s)John Parkinson
A small study is reporting very few adverse effects and low rates of COVID-19 transmission rates from mother to baby.
Advertisement
A small study is reporting very few adverse effects and low rates of COVID-19 transmission rates from mothers to newborns. Investigators from the University of California San Francisco looked at adverse outcomes, including preterm birth, NICU admission, and respiratory disease, and found they did not differ between those born to mothers testing positive for SARS-CoV-2 and those babies born to mothers testing negative.
In addition, no pneumonia or lower respiratory tract infections were diagnosed in the newborns up through eight weeks of age.
The study looked at 263 infants total with 179 testing positive for SARS-CoV-2 and 84 negative. Of the 263 infants, 44 were admitted to a NICU but no pneumonia or lower respiratory tract infections were reported during the study. Among the 56 infants assessed for upper respiratory infection, it was reported in two infants with COVID-positive mothers, and in one with a COVID-negative mother.
The babies are doing well, and that's wonderful," lead author Valerie J. Flaherman, MD, MPH, associate professor of pediatrics and of epidemiology and biostatistics at UCSF, said. "When coronavirus first hit, there were so many strange and unfortunate issues tied to it, but there was almost no information on how COVID-19 impacts pregnant women and their newborns. We didn't know what to expect for the babies, so this is good new
The findings will be published in the journal Clinical Infectious Diseases.
In terms of transmission, in the babies born to mothers who tested positive, the estimated incidence of a positive infant SARS-CoV-2 test was low at 1.1%. And COVID did not appear to impact those infants, the authors said.
The investigators did caution more needs to be studied before making more comprehensive conclusions.
"Overall, the initial findings regarding infant health are reassuring, but it's important to note that the majority of these births were from third trimester infections," said senior author Stephanie L. Gaw, MD, PhD, assistant professor of obstetrics, gynecology and reproductive sciences at UCSF. "The outcomes from our complete cohort will give the full picture of risks throughout pregnancy."
Advertisement
Related to this article
The Vaccine Integrity Project, in collaboration with the American Medical Association, conducted a vaccine and immunization effectiveness and safety review for RSV, Influenza, and COVID-19 for the 2026-2027 season. JAMA published the review, and here is an overview of the data going into this year's seasonal respiratory virus season.
The antiviral did not produce greater symptom improvement than placebo in patients with the condition in the RECOVER-VITAL trial.
The FDA has approved formulations for the 2026-2027 vaccines including Pfizer-BioNTech's Comirnaty XFG, Novavax's commercial partners Sanofi and Takeda have secured approvals for its Nuvaxovid, and Moderna's Spikevax and mNEXSPIKE vaccines, all with protections against the currently circulating variant.
The FDA has approved Pfizer-BioNTech's 2026-2027 Comirnaty XFG formula, an updated COVID-19 vaccine targeting the XFG variant, for adults 65 and older and for individuals ages five through 64 with at least one high-risk underlying condition.
Investigators accessed longitudinal human data from ebola virus vaccination for signals of efficacy against the Bundibugyo species now surging in the Democratic Republic of Congo.
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.